

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in cholangiocarcinomas and share hypermethylation target sites

Oncogene

32, 3091-3100

DOI: [10.1038/onc.2012.315](https://doi.org/10.1038/onc.2012.315)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Adjuvant Therapy for Intrahepatic Cholangiocarcinoma: The Debate Continues. <i>Oncologist</i> , 2012, 17, 1504-1507. | 1.9 | 24 |
| 2 | Isocitrate Dehydrogenase (IDH) Mutations Promote a Reversible ZEB1/MicroRNA (miR)-200-dependent Epithelial-Mesenchymal Transition (EMT). <i>Journal of Biological Chemistry</i> , 2012, 287, 42180-42194. | 1.6 | 86 |
| 3 | Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and 1 α -KG. <i>Acta Neuropathologica Communications</i> , 2013, 1, 18. | 2.4 | 54 |
| 4 | The CpG Island Methylator Phenotype: What's in a Name?. <i>Cancer Research</i> , 2013, 73, 5858-5868. | 0.4 | 154 |
| 5 | Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. <i>Nature Genetics</i> , 2013, 45, 1470-1473. | 9.4 | 564 |
| 6 | Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. <i>Nature Genetics</i> , 2013, 45, 1474-1478. | 9.4 | 426 |
| 7 | IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. <i>Future Oncology</i> , 2013, 9, 1923-1935. | 1.1 | 53 |
| 8 | Metabolic Mechanisms of Epigenetic Regulation. <i>ACS Chemical Biology</i> , 2013, 8, 2607-2621. | 1.6 | 63 |
| 9 | Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma. <i>Gastroenterology</i> , 2013, 145, 1215-1229. | 0.6 | 978 |
| 10 | Genomic Decoding of Intrahepatic Cholangiocarcinoma Reveals Therapeutic Opportunities. <i>Gastroenterology</i> , 2013, 144, 687-690. | 0.6 | 18 |
| 11 | Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. <i>Nature Biotechnology</i> , 2013, 31, 213-219. | 9.4 | 3,934 |
| 12 | Metabolic alteration in tumorigenesis. <i>Science China Life Sciences</i> , 2013, 56, 1067-1075. | 2.3 | 19 |
| 13 | 5-hydroxymethylcytosine profiling as an indicator of cellular state. <i>Epigenomics</i> , 2013, 5, 655-669. | 1.0 | 52 |
| 14 | Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2. <i>Nature Communications</i> , 2013, 4, 2166. | 5.8 | 152 |
| 15 | The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System Neoplasms. <i>Frontiers in Oncology</i> , 2013, 3, 169. | 1.3 | 44 |
| 16 | DNA Damage, DNA Repair and Cancer. , 0, , . | | 40 |
| 17 | Diverse modes of genomic alteration in hepatocellular carcinoma. <i>Genome Biology</i> , 2014, 15, 436. | 3.8 | 100 |
| 18 | Cholangiocarcinoma: Molecular Pathways and Therapeutic Opportunities. <i>Seminars in Liver Disease</i> , 2014, 34, 456-464. | 1.8 | 106 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma. <i>PLoS Genetics</i> , 2014, 10, e1004135. | 1.5 | 292 |
| 20 | Molecular Pathogenesis of Cholangiocarcinoma. <i>Digestive Diseases</i> , 2014, 32, 564-569. | 0.8 | 35 |
| 21 | IDH mutations in liver cell plasticity and biliary cancer. <i>Cell Cycle</i> , 2014, 13, 3176-3182. | 1.3 | 30 |
| 22 | Mutational landscape of intrahepatic cholangiocarcinoma. <i>Nature Communications</i> , 2014, 5, 5696. | 5.8 | 314 |
| 23 | Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients. <i>Leukemia</i> , 2014, 28, 2422-2424. | 3.3 | 52 |
| 24 | Isocitrate dehydrogenase mutations in chondrosarcoma. <i>Current Opinion in Oncology</i> , 2014, 26, 403-407. | 1.1 | 9 |
| 25 | A perspective on molecular therapy in cholangiocarcinoma: present status and future directions. <i>Hepatic Oncology</i> , 2014, 1, 143-157. | 4.2 | 16 |
| 26 | New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing. <i>Oncologist</i> , 2014, 19, 235-242. | 1.9 | 371 |
| 27 | Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 295-302. | 1.0 | 42 |
| 28 | TET enzymatic oxidation of 5-methylcytosine, 5-hydroxymethylcytosine and 5-formylcytosine. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2014, 764-765, 18-35. | 0.9 | 45 |
| 29 | High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers. <i>Gastric Cancer</i> , 2014, 17, 442-449. | 2.7 | 52 |
| 30 | Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2014, 60, 1268-1289. | 1.8 | 1,151 |
| 31 | Cholangiocarcinoma. <i>Lancet, The</i> , 2014, 383, 2168-2179. | 6.3 | 1,350 |
| 32 | Metabolic requirements for the maintenance of self-renewing stem cells. <i>Nature Reviews Molecular Cell Biology</i> , 2014, 15, 243-256. | 16.1 | 848 |
| 33 | Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 1884-1890. | 3.2 | 110 |
| 34 | Pan-cancer patterns of DNA methylation. <i>Genome Medicine</i> , 2014, 6, 66. | 3.6 | 149 |
| 35 | Serum 2-Hydroxyglutarate Production in <i>IDH1</i> - and <i>IDH2</i> -Mutated De Novo Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 297-305. | 0.8 | 109 |
| 36 | Primary acute myeloid leukemia cells with <i>IDH1</i> or <i>IDH2</i> mutations respond to a <i>DOT1L</i> inhibitor in vitro. <i>Leukemia</i> , 2014, 28, 2403-2406. | 3.3 | 36 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | The role of mutation of metabolism-related genes in genomic hypermethylation. <i>Biochemical and Biophysical Research Communications</i> , 2014, 455, 16-23. | 1.0 | 25 |
| 38 | Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets. <i>Annals of Surgical Oncology</i> , 2014, 21, 3827-3834. | 0.7 | 123 |
| 39 | IDH1 Mutations Alter Citric Acid Cycle Metabolism and Increase Dependence on Oxidative Mitochondrial Metabolism. <i>Cancer Research</i> , 2014, 74, 3317-3331. | 0.4 | 224 |
| 40 | Mutant IDH inhibits HNF-4 β to block hepatocyte differentiation and promote biliary cancer. <i>Nature</i> , 2014, 513, 110-114. | 13.7 | 367 |
| 41 | Exploration of liver cancer genomes. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 340-349. | 8.2 | 168 |
| 42 | The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 326-341. | 3.3 | 118 |
| 43 | Molecular diagnosis of intrahepatic cholangiocarcinoma. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2015, 22, 114-123. | 1.4 | 34 |
| 44 | IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. <i>Scientific Reports</i> , 2015, 5, 16238. | 1.6 | 259 |
| 45 | Role of Hepatocyte Nuclear Factor 4 β (HNF4 β) in Cell Proliferation and Cancer. <i>Gene Expression</i> , 2015, 16, 101-108. | 0.5 | 123 |
| 46 | Global DNA methylation and hydroxymethylation differ in hepatocellular carcinoma and cholangiocarcinoma and relate to survival rate. <i>Hepatology</i> , 2015, 62, 496-504. | 3.6 | 53 |
| 47 | Genetics of <i>Opisthorchis viverrini</i> -related cholangiocarcinoma. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 258-263. | 1.0 | 45 |
| 48 | Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 264-268. | 1.0 | 44 |
| 49 | Epigenetic Reduction of DNA Repair in Progression to Cancer. , 2015, , . | | 0 |
| 50 | New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma. <i>International Journal of Medical Sciences</i> , 2015, 12, 201-213. | 1.1 | 83 |
| 51 | An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma. <i>International Journal of Genomics</i> , 2015, 2015, 1-16. | 0.8 | 19 |
| 52 | IDH1, a CHOP and C/EBP β -responsive gene under ER stress, sensitizes human melanoma cells to hypoxia-induced apoptosis. <i>Cancer Letters</i> , 2015, 365, 201-210. | 3.2 | 43 |
| 53 | Extreme Vulnerability of IDH1 Mutant Cancers to NAD ⁺ Depletion. <i>Cancer Cell</i> , 2015, 28, 773-784. | 7.7 | 327 |
| 54 | Consensus Conference on Hilar Cholangiocarcinoma. <i>Hpb</i> , 2015, 17, 666-668. | 0.1 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | 5-Hydroxymethylcytosine: An epigenetic mark frequently deregulated in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 144-154. | 3.3 | 69 |
| 56 | Role of 5-hydroxymethylcytosine level in diagnosis and prognosis prediction of intrahepatic cholangiocarcinoma. <i>Tumor Biology</i> , 2015, 36, 2763-2771. | 0.8 | 21 |
| 57 | Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2015, 29, 233-244. | 1.0 | 34 |
| 58 | Epigenetic reduction of DNA repair in progression to gastrointestinal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2015, 7, 30. | 0.8 | 26 |
| 59 | IDH1, lipid metabolism and cancer: Shedding new light on old ideas. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2015, 1850, 1781-1785. | 1.1 | 33 |
| 60 | Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing. <i>Experimental and Molecular Pathology</i> , 2015, 99, 240-244. | 0.9 | 39 |
| 61 | Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases. <i>Modern Pathology</i> , 2015, 28, 1249-1264. | 2.9 | 85 |
| 62 | Future directions in the treatment of cholangiocarcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2015, 29, 355-361. | 1.0 | 29 |
| 63 | Liver cancer oncogenomics: opportunities and dilemmas for clinical applications. <i>Hepatic Oncology</i> , 2015, 2, 79-93. | 4.2 | 16 |
| 64 | Oncometabolites: tailoring our genes. <i>FEBS Journal</i> , 2015, 282, 2796-2805. | 2.2 | 112 |
| 65 | Molecular docking and molecular dynamics studies reveal structural basis of inhibition and selectivity of inhibitors EGCG and OSU-03012 toward glucose regulated protein-78 (GRP78) overexpressed in glioblastoma. <i>Journal of Molecular Modeling</i> , 2015, 21, 272. | 0.8 | 44 |
| 66 | CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 13982-13987. | 3.3 | 172 |
| 67 | Functional and genetic deconstruction of the cellular origin in liver cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 653-667. | 12.8 | 249 |
| 68 | Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. <i>Oncologist</i> , 2015, 20, 1019-1027. | 1.9 | 112 |
| 69 | Radioprotection of <i>IDH1</i> -Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. <i>Cancer Research</i> , 2015, 75, 4790-4802. | 0.4 | 127 |
| 70 | NADP ⁺ -IDH Mutations Promote Hypersuccinylation that Impairs Mitochondria Respiration and Induces Apoptosis Resistance. <i>Molecular Cell</i> , 2015, 60, 661-675. | 4.5 | 175 |
| 71 | Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas. <i>Brain Tumor Pathology</i> , 2015, 32, 3-11. | 1.1 | 62 |
| 72 | Molecular pathogenesis of intrahepatic cholangiocarcinoma. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2015, 22, 101-113. | 1.4 | 51 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Personalized Epigenetics. , 2016, , 843-858. | | 2 |
| 74 | Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation. <i>Frontiers in Oncology</i> , 2016, 6, 16. | 1.3 | 60 |
| 75 | The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 86. | 3.5 | 69 |
| 76 | Beyond the Oncogene Revolution: Four New Ways to Combat Cancer. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2016, 81, 85-92. | 2.0 | 6 |
| 77 | Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , 2016, 6, 727-739. | 7.7 | 126 |
| 78 | Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 261-280. | 8.2 | 964 |
| 79 | Maffucci syndrome and neoplasms: a case report and review of the literature. <i>BMC Research Notes</i> , 2016, 9, 126. | 0.6 | 37 |
| 80 | Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. <i>Oncologist</i> , 2016, 21, 594-599. | 1.9 | 548 |
| 81 | The potential role of liver stem cells in initiation of primary liver cancer. <i>Hepatology International</i> , 2016, 10, 893-901. | 1.9 | 8 |
| 82 | Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice. <i>Current Treatment Options in Oncology</i> , 2016, 17, 58. | 1.3 | 88 |
| 83 | Molecular characteristics of biliary tract cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 107, 111-118. | 2.0 | 29 |
| 84 | Mutant IDH1 and thrombosis in gliomas. <i>Acta Neuropathologica</i> , 2016, 132, 917-930. | 3.9 | 130 |
| 85 | Molecular Pathogenesis and Current Therapy in Intrahepatic Cholangiocarcinoma. <i>Digestive Diseases</i> , 2016, 34, 440-451. | 0.8 | 20 |
| 86 | A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model. <i>Journal of Inherited Metabolic Disease</i> , 2016, 39, 807-820. | 1.7 | 11 |
| 87 | Cholangiocarcinoma and Gallbladder Cancer. , 2016, , 423-471. | | 0 |
| 88 | Epigenetic therapy in gastrointestinal cancer: the right combination. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 560-579. | 1.4 | 81 |
| 89 | A holistic view of cancer bioenergetics: mitochondrial function and respiration play fundamental roles in the development and progression of diverse tumors. <i>Clinical and Translational Medicine</i> , 2016, 5, 3. | 1.7 | 65 |
| 90 | The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology. <i>Annals of Surgical Oncology</i> , 2016, 23, 290-296. | 0.7 | 80 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients. <i>Annals of Surgical Oncology</i> , 2016, 23, 1699-1707. | 0.7 | 76 |
| 92 | Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 291-300. | 3.2 | 185 |
| 93 | <i>l2hgdh</i> Deficiency Accumulates <i>l2hgdh</i> -2-Hydroxyglutarate with Progressive Leukoencephalopathy and Neurodegeneration. <i>Molecular and Cellular Biology</i> , 2017, 37, . | 1.1 | 27 |
| 94 | 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. <i>Science Translational Medicine</i> , 2017, 9, . | 5.8 | 420 |
| 95 | Advances in the molecular characterization of liver tumors. , 2017, , 133-138.e2. | | 0 |
| 96 | Molecular pathogenesis of biliary tract cancer. , 2017, , 150-159.e2. | | 1 |
| 97 | Signaling pathways as therapeutic targets in biliary tract cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 485-498. | 1.5 | 4 |
| 98 | Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 349-356. | 1.4 | 16 |
| 99 | Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis. <i>Surgical Oncology</i> , 2017, 26, 125-137. | 0.8 | 99 |
| 100 | Clinicopathological, radiologic, and molecular study of 23 combined hepatocellular-cholangiocarcinomas with stem cell features, cholangiolocellular type. <i>Human Pathology</i> , 2017, 64, 118-127. | 1.1 | 23 |
| 101 | The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 507-520. | 1.4 | 47 |
| 102 | Accuracy of 1H magnetic resonance spectroscopy for quantification of 2-hydroxyglutarate using linear combination and J-difference editing at 9.4 T. <i>Zeitschrift Fur Medizinische Physik</i> , 2017, 27, 300-309. | 0.6 | 2 |
| 103 | Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?. <i>European Journal of Cancer</i> , 2017, 81, 161-173. | 1.3 | 27 |
| 104 | Understanding liver regeneration to bring new insights to the mechanisms driving cholangiocarcinoma. <i>Npj Regenerative Medicine</i> , 2017, 2, 13. | 2.5 | 10 |
| 105 | Update on cholangiocarcinoma: potential impact of genomic studies on clinical management. <i>Zeitschrift Fur Gastroenterologie</i> , 2017, 55, 575-581. | 0.2 | 25 |
| 106 | Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas. <i>Modern Pathology</i> , 2017, 30, 986-997. | 2.9 | 84 |
| 107 | Emerging molecular therapeutic targets for cholangiocarcinoma. <i>Journal of Hepatology</i> , 2017, 67, 632-644. | 1.8 | 150 |
| 108 | Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. <i>Cell Reports</i> , 2017, 18, 2780-2794. | 2.9 | 416 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Intrahepatic cholangiocarcinoma: current management and emerging therapies. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 439-449. | 1.4 | 58 |
| 110 | Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. <i>Gastroenterology</i> , 2017, 152, 745-761. | 0.6 | 838 |
| 111 | Cholangiocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 116, 11-31. | 2.0 | 96 |
| 112 | Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy. <i>BioDrugs</i> , 2017, 31, 379-392. | 2.2 | 8 |
| 113 | Measurement of Oncometabolites d-2-Hydroxyglutaric Acid and l-2-Hydroxyglutaric Acid. <i>Methods in Molecular Biology</i> , 2017, 1633, 219-234. | 0.4 | 7 |
| 114 | New Horizons for Precision Medicine in Biliary Tract Cancers. <i>Cancer Discovery</i> , 2017, 7, 943-962. | 7.7 | 419 |
| 115 | IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing. <i>World Journal of Surgical Oncology</i> , 2017, 15, 82. | 0.8 | 22 |
| 116 | IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas. <i>Clinical Sarcoma Research</i> , 2017, 7, 8. | 2.3 | 50 |
| 118 | Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. <i>Cancer Discovery</i> , 2017, 7, 1116-1135. | 7.7 | 637 |
| 119 | Cancer Stem Cells and Aldehyde Dehydrogenase 1 in Liver Cancers. , 2017, , . | | 2 |
| 120 | Regulation and Functional Significance of 5-Hydroxymethylcytosine in Cancer. <i>Epigenomes</i> , 2017, 1, 19. | 0.8 | 6 |
| 121 | Therapeutic options for intrahepatic cholangiocarcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 6, 91-100. | 0.7 | 13 |
| 122 | Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 387-404. | 0.6 | 21 |
| 123 | Current biologics for treatment of biliary tract cancers. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 430-440. | 0.6 | 33 |
| 124 | Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 293-301. | 0.6 | 47 |
| 125 | Intrahepatic cholangiocarcinoma: can imaging phenotypes predict survival and tumor genetics?. <i>Abdominal Radiology</i> , 2018, 43, 2665-2672. | 1.0 | 30 |
| 126 | Resistance Mechanisms to Targeted Therapies in <i>ROS1</i> + and <i>ALK</i> + Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3334-3347. | 3.2 | 182 |
| 127 | Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates. <i>Trends in Cancer</i> , 2018, 4, 151-165. | 3.8 | 160 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 128 | Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 694-699. | 1.0 | 18 |
| 129 | Wild-type and mutated IDH1/2 enzymes and therapy responses. <i>Oncogene</i> , 2018, 37, 1949-1960. | 2.6 | 169 |
| 130 | Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase- α -mutated intrahepatic cholangiocarcinomas. <i>European Journal of Cancer</i> , 2018, 90, 83-91. | 1.3 | 28 |
| 131 | Epigenome dysregulation in cholangiocarcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1423-1434. | 1.8 | 31 |
| 132 | Predicting IDH mutation status of intrahepatic cholangiocarcinomas based on contrast-enhanced CT features. <i>European Radiology</i> , 2018, 28, 159-169. | 2.3 | 10 |
| 133 | Implications of Intrahepatic Cholangiocarcinoma Etiology on Recurrence and Prognosis after Curative-Intent Resection: a Multi-Institutional Study. <i>World Journal of Surgery</i> , 2018, 42, 849-857. | 0.8 | 17 |
| 134 | The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1468-1477. | 1.8 | 72 |
| 135 | Tissue is the Issue: Biomarkers of Prognosis and Classification in Adult Gliomas. <i>Seminars in Oncology Nursing</i> , 2018, 34, 430-442. | 0.7 | 5 |
| 136 | Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5957-5962. | 1.0 | 19 |
| 137 | Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas. <i>Cancer Genomics and Proteomics</i> , 2018, 15, 421-436. | 1.0 | 9 |
| 138 | Emerging role of precision medicine in biliary tract cancers. <i>Npj Precision Oncology</i> , 2018, 2, 21. | 2.3 | 27 |
| 139 | IDH1 mutation correlates with a beneficial prognosis and suppresses tumor growth in IHCC. <i>Journal of Surgical Research</i> , 2018, 231, 116-125. | 0.8 | 13 |
| 140 | Genomics of Peritoneal Malignancies. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 463-475. | 0.6 | 14 |
| 141 | IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity. <i>FASEB Journal</i> , 2018, 32, 6344-6352. | 0.2 | 28 |
| 142 | Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic Resistance. <i>World Neurosurgery</i> , 2018, 116, 505-517. | 0.7 | 105 |
| 143 | Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies. <i>Cancers</i> , 2018, 10, 49. | 1.7 | 31 |
| 144 | Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation. <i>Cancer Letters</i> , 2018, 429, 1-10. | 3.2 | 14 |
| 145 | Cholangiocarcinoma. <i>Surgical Pathology Clinics</i> , 2018, 11, 403-429. | 0.7 | 92 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 146 | A Nexus model of cellular transition in cancer. <i>Biological Research</i> , 2018, 51, 23. | 1.5 | 1 |
| 147 | Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 6433-6446. | 3.2 | 54 |
| 148 | Novel targeted treatment options for advanced cholangiocarcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 709-720. | 1.9 | 42 |
| 149 | New developments in systemic therapy for advanced biliary tract cancer. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 703-711. | 0.6 | 64 |
| 150 | Molecular Pathogenesis: From Inflammation and Cholestasis to a Microenvironment-Driven Tumor. , 2019, , 167-182. | | 0 |
| 151 | Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 711-720. | 3.7 | 161 |
| 152 | Epigenome Remodeling in Cholangiocarcinoma. <i>Trends in Cancer</i> , 2019, 5, 335-350. | 3.8 | 36 |
| 154 | The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis. <i>Cell Death and Disease</i> , 2019, 10, 755. | 2.7 | 46 |
| 155 | Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug Targets. <i>IScience</i> , 2019, 21, 624-637. | 1.9 | 15 |
| 156 | Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 751-765. | 0.6 | 105 |
| 157 | Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information. <i>Scientific Reports</i> , 2019, 9, 13261. | 1.6 | 66 |
| 158 | Mitogen-Activated Protein Kinases (MAPKs) and Cholangiocarcinoma: The Missing Link. <i>Cells</i> , 2019, 8, 1172. | 1.8 | 29 |
| 159 | Distinct histomorphological features are associated with IDH1 mutation in intrahepatic cholangiocarcinoma. <i>Human Pathology</i> , 2019, 91, 19-25. | 1.1 | 12 |
| 160 | Coming of a precision era of the staging systems for intrahepatic cholangiocarcinoma?. <i>Cancer Letters</i> , 2019, 460, 10-17. | 3.2 | 11 |
| 161 | Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers. <i>Scientific Reports</i> , 2019, 9, 8946. | 1.6 | 44 |
| 162 | Therapeutic Potential of Pharmacoepigenetics in Cholangiocarcinoma. , 2019, , 551-562. | | 0 |
| 163 | Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2020, 112, 200-210. | 3.0 | 90 |
| 164 | <p>Biliary tract cancers: current knowledge, clinical candidates and future challenges</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 2623-2642. | 0.9 | 78 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 165 | Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver International, 2019, 39, 7-18. | 1.9 | 193 |
| 166 | Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?. Liver International, 2019, 39, 32-42. | 1.9 | 21 |
| 167 | Diagnostic and prognostic biomarkers in cholangiocarcinoma. Liver International, 2019, 39, 108-122. | 1.9 | 89 |
| 168 | The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine. Journal of Autoimmunity, 2019, 100, 17-26. | 3.0 | 33 |
| 169 | Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications. Leukemia and Lymphoma, 2019, 60, 2635-2645. | 0.6 | 6 |
| 170 | Assessment of a High Sensitivity Method for Identification of IDH1 R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients. Cancers, 2019, 11, 454. | 1.7 | 4 |
| 171 | Tissue 2-Hydroxyglutarate as a Biomarker for <i>Isocitrate Dehydrogenase</i> Mutations in Gliomas. Clinical Cancer Research, 2019, 25, 3366-3373. | 3.2 | 17 |
| 172 | Molecular Characteristics of Biliary Tract and Primary Liver Tumors. Surgical Oncology Clinics of North America, 2019, 28, 685-693. | 0.6 | 6 |
| 173 | Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers. Scientific Reports, 2019, 9, 16830. | 1.6 | 29 |
| 174 | Genetic Mouse Models as In Vivo Tools for Cholangiocarcinoma Research. Cancers, 2019, 11, 1868. | 1.7 | 5 |
| 175 | Metabolic rearrangements in primary liver cancers: cause and consequences. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 748-766. | 8.2 | 144 |
| 176 | Specific prognostic factors in hepatitis B virus-related and non-hepatitis B virus-related intrahepatic cholangiocarcinoma after macroscopic curative resection. Journal of Surgical Oncology, 2019, 119, 40-46. | 0.8 | 11 |
| 177 | Coupling Krebs cycle metabolites to signalling in immunity and cancer. Nature Metabolism, 2019, 1, 16-33. | 5.1 | 260 |
| 178 | Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma. Hepatology, 2019, 69, 2091-2106. | 3.6 | 63 |
| 179 | A Case of Metastatic Biliary Tract Cancer Diagnosed Through Identification of an IDH1 Mutation. Oncologist, 2019, 24, 151-156. | 1.9 | 1 |
| 180 | Animal models of cholangiocarcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 982-992. | 1.8 | 50 |
| 181 | Emerging pathways for precision medicine in management of cholangiocarcinoma. Surgical Oncology, 2020, 35, 47-55. | 0.8 | 5 |
| 182 | Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options. Cancers, 2020, 12, 3370. | 1.7 | 28 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 183 | Isocitrate dehydrogenase variants in cancer – Cellular consequences and therapeutic opportunities. <i>Current Opinion in Chemical Biology</i> , 2020, 57, 122-134. | 2.8 | 35 |
| 184 | Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 429-438. | 0.4 | 2 |
| 185 | Frequency and Prognostic Value of IDH Mutations in Korean Patients With Cholangiocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1514. | 1.3 | 6 |
| 186 | PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?. <i>Medicines (Basel, Switzerland)</i> , 2020, 7, 54. | 0.7 | 21 |
| 187 | IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment – Current State and Future Perspectives. <i>Molecules</i> , 2020, 25, 3754. | 1.7 | 18 |
| 188 | Evolution of the Experimental Models of Cholangiocarcinoma. <i>Cancers</i> , 2020, 12, 2308. | 1.7 | 76 |
| 189 | Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas. <i>Science Advances</i> , 2020, 6, eaaz3221. | 4.7 | 67 |
| 190 | Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClariDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 796-807. | 5.1 | 620 |
| 191 | IDH-Mutant Gliomas. , 2020, , . | | 4 |
| 192 | Lower Grade Gliomas. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 21. | 2.0 | 68 |
| 193 | Progress and prospects of biomarkers in primary liver cancer (Review). <i>International Journal of Oncology</i> , 2020, 57, 54-66. | 1.4 | 43 |
| 194 | Molecular targeted therapies: Ready for prime time in biliary tract cancer. <i>Journal of Hepatology</i> , 2020, 73, 170-185. | 1.8 | 226 |
| 195 | Targets for therapy in biliary tract cancers: the new horizon of personalized medicine. <i>Chinese Clinical Oncology</i> , 2020, 9, 7-7. | 0.4 | 4 |
| 196 | Therapeutic Potential of Autophagy Modulation in Cholangiocarcinoma. <i>Cells</i> , 2020, 9, 614. | 1.8 | 22 |
| 197 | Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588. | 8.2 | 1,155 |
| 198 | Systemic therapies for intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2020, 72, 353-363. | 1.8 | 235 |
| 199 | Is the IDH Mutation a Good Target for Chondrosarcoma Treatment?. <i>Current Molecular Biology Reports</i> , 2020, 6, 1-9. | 0.8 | 20 |
| 200 | Utility of DNA flow cytometry in distinguishing between malignant and benign intrahepatic biliary lesions. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 527-534. | 1.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 201 | Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma. BMC Cancer, 2020, 20, 318. | 1.1 | 49 |
| 202 | Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. Cancer Treatment Reviews, 2020, 86, 101998. | 3.4 | 25 |
| 203 | Molecular Targets in Cholangiocarcinoma. Hepatology, 2021, 73, 62-74. | 3.6 | 26 |
| 204 | Tenâ€Eleven Translocation 1 Promotes Malignant Progression of Cholangiocarcinoma With Wildâ€™type Isocitrate Dehydrogenase 1. Hepatology, 2021, 73, 1747-1763. | 3.6 | 20 |
| 205 | Sirtuin activation targets IDH-mutant tumors. Neuro-Oncology, 2021, 23, 53-62. | 0.6 | 15 |
| 206 | Otto Warburg: The journey towards the seminal discovery of tumor cell bioenergetic reprogramming. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 165965. | 1.8 | 19 |
| 207 | Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy. Expert Opinion on Investigational Drugs, 2021, 30, 365-375. | 1.9 | 10 |
| 208 | The presence of TIMâ€™3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status. Brain Pathology, 2021, 31, e12921. | 2.1 | 5 |
| 209 | Therapy for advanced cholangiocarcinoma: Current knowledge and future potential. Journal of Cellular and Molecular Medicine, 2021, 25, 618-628. | 1.6 | 18 |
| 210 | Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. Advances in Cancer Research, 2021, 149, 321-387. | 1.9 | 18 |
| 211 | Quality and performance of validated prognostic models for survival after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. Hpb, 2021, 23, 25-36. | 0.1 | 16 |
| 212 | Precision Medicine for Pancreatic Cancer and Cholangiocarcinoma. , 2021, , 171-184. | | 0 |
| 213 | Established and Emerging Biomarkers for Prediction, Early Detection, and Prognostication of Cholangiocarcinoma. , 2021, , 413-434. | | 0 |
| 214 | Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors. Cancer Control, 2021, 28, 107327482198931. | 0.7 | 2 |
| 215 | Gut Microbiome and Liver Cancer. Physiology in Health and Disease, 2021, , 199-255. | 0.2 | 0 |
| 216 | Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview. OncoTargets and Therapy, 2021, Volume 14, 1341-1366. | 1.0 | 12 |
| 217 | Clinical Efficacy of Olaparib in <i>IDH1/IDH2-</i>Mutant Mesenchymal Sarcomas. JCO Precision Oncology, 2021, 5, 466-472. | 1.5 | 24 |
| 218 | Epigenetic Regulatory Enzymes: mutation Prevalence and Coexistence in Cancers. Cancer Investigation, 2021, 39, 257-273. | 0.6 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 219 | The Clinical Management of Cholangiocarcinoma in the United States and Europe: A Comprehensive and Evidence-Based Comparison of Guidelines. <i>Annals of Surgical Oncology</i> , 2021, 28, 2660-2674. | 0.7 | 38 |
| 220 | Cholangiocarcinoma: shedding light on the most promising drugs in clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 419-427. | 1.9 | 5 |
| 221 | Value of contrast-enhanced CT texture analysis in predicting IDH mutation status of intrahepatic cholangiocarcinoma. <i>Scientific Reports</i> , 2021, 11, 6933. | 1.6 | 9 |
| 222 | Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]? <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 463-477. | 1.9 | 19 |
| 223 | Current challenges to underpinning the genetic basis for cholangiocarcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 511-526. | 1.4 | 3 |
| 224 | Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 475-481. | 1.4 | 2 |
| 225 | Next-Generation Biomarkers for Cholangiocarcinoma. <i>Cancers</i> , 2021, 13, 3222. | 1.7 | 20 |
| 226 | The implications of IDH mutations for cancer development and therapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 645-661. | 12.5 | 155 |
| 227 | DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma. <i>Aging</i> , 2021, 13, 17592-17606. | 1.4 | 8 |
| 228 | Integrated Analysis of the Clinical and Molecular Characteristics of IDH Wild-Type Gliomas in the Chinese Glioma Genome Atlas. <i>Frontiers in Oncology</i> , 2021, 11, 696214. | 1.3 | 3 |
| 229 | <i>IDH</i> Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma. <i>Advanced Science</i> , 2021, 8, e2101230. | 5.6 | 26 |
| 230 | Significant Response to Camrelizumab Plus Targeted Drugs in Recurrent Intrahepatic Cholangiocarcinoma: a Case Report and Literature Review. <i>Journal of Gastrointestinal Cancer</i> , 2022, 53, 817-824. | 0.6 | 3 |
| 231 | Molecular-driven treatment for biliary tract cancer: the promising turning point. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1253-1264. | 1.1 | 0 |
| 232 | Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers. <i>Cancer Science</i> , 2021, 112, 4819-4833. | 1.7 | 4 |
| 233 | Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. <i>Hepatology</i> , 2021, 74, 1429-1444. | 3.6 | 73 |
| 234 | Mechanism of cholangiocellular damage and repair during cholestasis. <i>Annals of Hepatology</i> , 2021, 26, 100530. | 0.6 | 2 |
| 235 | Cholangiocarcinoma Therapeutics: An Update. <i>Current Cancer Drug Targets</i> , 2021, 21, 457-475. | 0.8 | 5 |
| 236 | Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-1. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1047-1056. | 1.9 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 237 | Valproic Acid Enhanced Temozolomide-Induced Anticancer Activity in Human Glioma Through the p53-PUMA Apoptosis Pathway. <i>Frontiers in Oncology</i> , 2021, 11, 722754. | 1.3 | 11 |
| 238 | R-2HG downregulates ER α to inhibit cholangiocarcinoma via the FTO/m6A-methylated ER α /miR16-5p/YAP1 signal pathway. <i>Molecular Therapy - Oncolytics</i> , 2021, 23, 65-81. | 2.0 | 14 |
| 239 | DNA direct reversal repair and alkylating agent drug resistance. , 2021, 4, 414-423. | | 7 |
| 240 | Proximity ligation assay evaluates IDH1R132H presentation in gliomas. <i>Journal of Clinical Investigation</i> , 2015, 125, 593-606. | 3.9 | 35 |
| 241 | Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 161-173. | 1.8 | 7 |
| 242 | IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma. <i>Medical Science Monitor</i> , 2014, 20, 247-254. | 0.5 | 10 |
| 243 | Reporting Tumor Molecular Heterogeneity in Histopathological Diagnosis. <i>PLoS ONE</i> , 2014, 9, e104979. | 1.1 | 35 |
| 244 | mIDH-associated DNA hypermethylation in acute myeloid leukemia reflects differentiation blockage rather than inhibition of TET-mediated demethylation. <i>Cell Stress</i> , 2017, 1, 55-67. | 1.4 | 3 |
| 245 | 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. <i>Oncotarget</i> , 2013, 4, 1737-1747. | 0.8 | 141 |
| 246 | Prognostic value of LINE-1 methylation level in 321 patients with primary liver cancer including hepatocellular carcinoma and intrahepatic cholangiocarcinoma. <i>Oncotarget</i> , 2018, 9, 20795-20806. | 0.8 | 14 |
| 247 | D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth. <i>Oncotarget</i> , 2015, 6, 8606-8620. | 0.8 | 46 |
| 248 | Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines. <i>Oncotarget</i> , 2015, 6, 12505-12519. | 0.8 | 81 |
| 249 | Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. <i>Oncotarget</i> , 2015, 6, 12279-12296. | 0.8 | 53 |
| 250 | The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2015, 6, 14832-14842. | 0.8 | 33 |
| 251 | Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations. <i>Oncotarget</i> , 2016, 7, 23825-23836. | 0.8 | 10 |
| 252 | The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. <i>Oncotarget</i> , 2016, 7, 46750-46767. | 0.8 | 97 |
| 253 | Biliary tract cancer prognostic and predictive genomics. <i>Chinese Clinical Oncology</i> , 2019, 8, 42-42. | 0.4 | 15 |
| 254 | Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice. <i>World Journal of Gastroenterology</i> , 2016, 22, 2071. | 1.4 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 255 | Emerging molecular targets and therapy for cholangiocarcinoma. World Journal of Gastrointestinal Oncology, 2017, 9, 268. | 0.8 | 27 |
| 256 | Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy. World Journal of Gastrointestinal Endoscopy, 2016, 8, 128. | 0.4 | 19 |
| 257 | Molecular heterogeneity in intrahepatic cholangiocarcinoma. World Journal of Hepatology, 2020, 12, 1148-1157. | 0.8 | 12 |
| 258 | Systemic treatment of advanced or recurrent biliary tract cancer. BioScience Trends, 2020, 14, 328-341. | 1.1 | 29 |
| 259 | Biliary Cancer. UNIPA Springer Series, 2021, , 675-688. | 0.1 | 0 |
| 260 | Role of autophagy in cholangiocarcinoma: An autophagy-based treatment strategy. World Journal of Gastrointestinal Oncology, 2021, 13, 1229-1243. | 0.8 | 9 |
| 261 | Cell-free DNA from bile outperformed plasma as a potential alternative to tissue biopsy in biliary tract cancer. ESMO Open, 2021, 6, 100275. | 2.0 | 18 |
| 262 | Emerging Anti-cancer Targets in Mitochondria. , 2014, , 265-290. | | 0 |
| 263 | Fighting Fire with Fire in Cancer. , 2015, , 39-49. | | 1 |
| 264 | Etiology and Pathogenic Pathways of Cholangiocarcinoma. , 2016, , 1-34. | | 0 |
| 265 | Etiology and Pathogenic Pathways of Cholangiocarcinoma. , 2017, , 605-638. | | 0 |
| 266 | Cancer Metabolism. , 2018, , 129-154. | | 0 |
| 267 | Management of Primary Malignant Hepatic Neoplasms Other Than Hepatocellular Cancer. , 2019, , 1556-1564. | | 0 |
| 268 | Hot topics in cholangiocarcinoma. Translational Cancer Research, 2019, 8, S219-S222. | 0.4 | 0 |
| 269 | Molecular genetic aspects of intrahepatic cholangiocarcinoma: literature review. Uspehi Molekularnoj Onkologii, 2019, 6, 37-43. | 0.1 | 4 |
| 270 | Personalized Medicine in Advanced Cholangiocarcinoma. Oncology & Hematology Review, 2020, 16, 52. | 0.2 | 1 |
| 271 | Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy. American Journal of Cancer Research, 2016, 6, 577-86. | 1.4 | 18 |
| 272 | Assessment of liver cancer biomarkers. Gastroenterology and Hepatology From Bed To Bench, 2020, 13, S29-S39. | 0.6 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 273 | Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities. <i>Theranostics</i> , 2022, 12, 260-276. | 4.6 | 16 |
| 274 | Oncometabolites as Regulators of DNA Damage Response and Repair. <i>Seminars in Radiation Oncology</i> , 2022, 32, 82-94. | 1.0 | 3 |
| 275 | Cancer metabolism and tumor microenvironment: fostering each other?. <i>Science China Life Sciences</i> , 2022, 65, 236-279. | 2.3 | 68 |
| 277 | An Enzymatic Biosensor for the Detection of D-2-Hydroxyglutaric Acid in Serum and Urine. <i>Biosensors</i> , 2022, 12, 66. | 2.3 | 6 |
| 278 | Molecular therapeutic targets for cholangiocarcinoma: Present challenges and future possibilities. <i>Advances in Cancer Research</i> , 2022, , . | 1.9 | 1 |
| 279 | New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3887. | 1.8 | 16 |
| 280 | Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study. <i>European Journal of Cancer</i> , 2022, 166, 165-175. | 1.3 | 17 |
| 281 | Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations. <i>Cell Reports Medicine</i> , 2021, 2, 100469. | 3.3 | 21 |
| 282 | Isocitrate dehydrogenase gene variants in cancer and their clinical significance. <i>Biochemical Society Transactions</i> , 2021, 49, 2561-2572. | 1.6 | 10 |
| 284 | SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors. <i>Cell Research</i> , 2022, 32, 638-658. | 5.7 | 19 |
| 285 | Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 200-223. | 0.5 | 7 |
| 286 | Metabolic reprogramming in cholangiocarcinoma. <i>Journal of Hepatology</i> , 2022, 77, 849-864. | 1.8 | 49 |
| 287 | Involvement of Epigenomic Factors in Bile Duct Cancer. <i>Seminars in Liver Disease</i> , 2022, 42, 202-211. | 1.8 | 0 |
| 288 | Advances in the systemic treatment of therapeutic approaches in biliary tract cancer. <i>ESMO Open</i> , 2022, 7, 100503. | 2.0 | 8 |
| 289 | Novel Radioiodinated and Radiofluorinated Analogues of FT-2102 for SPECT or PET Imaging of mIDH1 Mutant Tumours. <i>Molecules</i> , 2022, 27, 3766. | 1.7 | 2 |
| 290 | RGS10 suppression by DNA methylation is associated with low survival rates in colorectal carcinoma. <i>Pathology Research and Practice</i> , 2022, 236, 154007. | 1.0 | 8 |
| 291 | Distinctive Metabolism-Associated Gene Clusters That Are Also Prognostic in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-22. | 1.9 | 7 |
| 292 | Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer. , 2022, , 761-776. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 293 | Cancer suppression by ferroptosis and its role in digestive system tumors. <i>World Chinese Journal of Digestology</i> , 2022, 30, 718-728. | 0.0 | 0 |
| 294 | Newest Therapies for Cholangiocarcinoma: An Updated Overview of Approved Treatments with Transplant Oncology Vision. <i>Cancers</i> , 2022, 14, 5074. | 1.7 | 9 |
| 295 | Treating Biliary Tract Cancers: New Targets and Therapies. <i>Drugs</i> , 2022, 82, 1629-1647. | 4.9 | 2 |
| 296 | Intrahepatic cholangiocarcinoma: The role of liver transplantation, adjunctive treatments, and prognostic biomarkers. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 6 |
| 297 | Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients. <i>Targeted Oncology</i> , 2023, 18, 139-145. | 1.7 | 1 |
| 298 | Primary Liver Cancers: Connecting the Dots of Cellular Studies and Epidemiology with Metabolomics. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2409. | 1.8 | 1 |
| 299 | Metabolic reprogramming and its clinical implication for liver cancer. <i>Hepatology</i> , 2023, 78, 1602-1624. | 3.6 | 10 |
| 300 | Unraveling the heterogeneity of cholangiocarcinoma and identifying biomarkers and therapeutic strategies with single-cell sequencing technology. <i>Biomedicine and Pharmacotherapy</i> , 2023, 162, 114697. | 2.5 | 1 |
| 301 | Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 257-264. | 1.1 | 0 |
| 302 | Impact of IDH1 mutation on clinical course of patients with intrahepatic cholangiocarcinoma: a retrospective analysis from a German tertiary center. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , . | 1.2 | 0 |
| 303 | Metabolic Rewiring in Adult-Type Diffuse Gliomas. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7348. | 1.8 | 2 |
| 304 | EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2023, 79, 181-208. | 1.8 | 33 |
| 314 | The role and implication of autophagy in cholangiocarcinoma. <i>Cell Death Discovery</i> , 2023, 9, . | 2.0 | 4 |
| 315 | The Hallmarks of Liver Fluke Related Cholangiocarcinoma: Insight into Drug Target Possibility. <i>Recent Results in Cancer Research</i> , 2023, , 53-90. | 1.8 | 0 |
| 324 | Editorial: Role of imaging in biliary tract cancer: diagnosis, staging, response prediction and image-guided therapeutics. <i>Frontiers in Oncology</i> , 0, 14, . | 1.3 | 0 |